Wedbush Downgrades Keros Therapeutics (NASDAQ:KROS) to Neutral

Wedbush cut shares of Keros Therapeutics (NASDAQ:KROS) from an outperform rating to a neutral rating in a research report report published on Friday, MarketBeat Ratings reports. Wedbush currently has $15.00 price target on the stock, down from their previous price target of $47.00.

KROS has been the topic of a number of other reports. Oppenheimer decreased their target price on Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating on the stock in a research report on Thursday. HC Wainwright lowered their price objective on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Truist Financial reduced their price target on shares of Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating on the stock in a report on Monday, December 23rd. Wells Fargo & Company raised their price objective on shares of Keros Therapeutics from $88.00 to $111.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Finally, Scotiabank reduced their target price on Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating on the stock in a research note on Thursday. Five investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $52.56.

Keros Therapeutics Stock Up 3.2 %

NASDAQ:KROS opened at $10.86 on Friday. The firm’s fifty day simple moving average is $37.51 and its 200-day simple moving average is $47.36. The stock has a market cap of $439.91 million, a PE ratio of -2.08 and a beta of 1.43. Keros Therapeutics has a fifty-two week low of $9.77 and a fifty-two week high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The company had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company’s quarterly revenue was up 4750.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.33) earnings per share. Equities analysts anticipate that Keros Therapeutics will post -4.74 earnings per share for the current year.

Institutional Investors Weigh In On Keros Therapeutics

Hedge funds have recently made changes to their positions in the business. FMR LLC lifted its position in Keros Therapeutics by 3.8% during the third quarter. FMR LLC now owns 4,899,134 shares of the company’s stock worth $284,493,000 after buying an additional 179,374 shares during the period. Alkeon Capital Management LLC increased its stake in shares of Keros Therapeutics by 18.7% during the 3rd quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock valued at $110,194,000 after acquiring an additional 298,694 shares during the last quarter. Darwin Global Management Ltd. lifted its holdings in shares of Keros Therapeutics by 6.3% during the 2nd quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company’s stock worth $68,772,000 after acquiring an additional 89,952 shares during the period. Point72 Asset Management L.P. grew its holdings in Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after purchasing an additional 577,220 shares during the period. Finally, Holocene Advisors LP increased its position in Keros Therapeutics by 22.5% during the third quarter. Holocene Advisors LP now owns 843,110 shares of the company’s stock worth $48,959,000 after purchasing an additional 154,784 shares during the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.